

EQA round: RFA2/23 - Risk Factors for Atherosclerosis

Deadline: 13.10.2023

Setup: groups - measurement principle; Slovakia; minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D _{max} = acceptable difference
SD = standard deviation	CVP = consensus of all participants	LL = lower limit
CV = coefficient of variation	U _{AV} = expanded uncertainty of the assigned value (k = 2)	UL = upper limit
N _{tot} = total number of the results		N _{eva} = number of the results assessed
N _{out} = number of the results removed before calculation		N _{suc} = number of successful results
		S _{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]
							AV	U _{AV}	D _{max}	LL	UL			
(114) Apolipoprotein AI	[g/L]				14							14	14	100
Sample A												14	14	100
(2) Immunoturbidimetry		2,32	0,2	8,7	14	0	CVP	2,31	0,037	21%	1,82	2,8	14	
Sample B												14	14	100
(2) Immunoturbidimetry		1,07	0,093	8,7	14	0	CVP	1,07	0,019	21%	0,845	1,3	14	
(115) Apolipoprotein B	[g/L]				16							16	14	88
Sample A												16	15	94
(2) Immunoturbidimetry		1,26	0,064	5,1	16	0	CVP	1,26	0,015	18%	1,03	1,49	16	
Sample B												16	14	88
(2) Immunoturbidimetry		0,549	0,028	5,1	16	0	CVP	0,555	0,009	18%	0,455	0,655	16	
(111) Cholesterol	[mmol/L]				40							40	39	98
Sample A												40	40	100
(0) Not specified		7,07	0,21	3	40	0	CVP	6,98	0,029	8%	6,42	7,54	40	
Sample B												40	39	98
(0) Not specified		3,08	0,091	2,9	40	0	CVP	3,05	0,013	8%	2,8	3,3	40	
(113) Cholesterol HDL	[mmol/L]				40							40	40	100
Sample A												40	40	100
(2) Direct determination		2,06	0,084	4,1	40		CVP	2,07	0,014	15%	1,75	2,39	40	
Other		2,06	0,085	4,1	39	0						39		
					1	0						1		
							1x 1							
Sample B												40	40	100
(2) Direct determination		0,971	0,043	4,4	40		CVP	0,988	0,006	15%	0,839	1,14	39	
Other		0,973	0,042	4,3	39	0						39		
					1	0						1		
							1x 1							
(118) Cholesterol LDL (direct determination)	[mmol/L]				34							34	34	100
Sample A												34	34	100
(0) Not specified		4,14	0,35	8,5	34	0	CVP	4,18	0,063	20%	3,34	5,02	34	
Sample B												34	34	100
(0) Not specified		1,78	0,11	6,3	34	0	CVP	1,79	0,022	20%	1,43	2,15	34	
(116) Cholesterol LDL (calculation)	[mmol/L]				9							9	9	100
Sample A												9	9	100
(0) Not specified		4,03	0,19	4,8	9	0	CVP	4	0,052	15%	3,4	4,6	9	
Sample B												9	9	100
(0) Not specified		1,76	0,089	5,1	9	0	CVP	1,66	0,027	15%	1,41	1,91	9	
(117) Lipoprotein (a) [g/L]	[g/L]				7							7	5	71
Sample A												7	6	86
(2) Immunoturbidimetry		0,259	0,031	12	7	0	CVP	0,277	0,009	25%	0,207	0,347	7	
Sample B												7	5	71
(2) Immunoturbidimetry		0,069	0,016	24	7	0	CVP	0,082	0,007	25%	0,061	0,103	7	
(119) Lipoprotein (a) [nmol/L]	[nmol/L]				4							4	4	100
Sample A												4	4	100
Other					4	0						4		
							4x 2							
Sample B												4	4	100
Other					4	0						4		
							4x 2							
(112) Triacylglycerols	[mmol/L]				38							38	38	100
Sample A												38	38	100
(1) Photometric enzyme (GPO-PAP)		2,08	0,052	2,5	38		CVP	2,08	0,009	15%	1,76	2,4	38	
Other		2,08	0,053	2,5	35	0						35		
					3	0						3		
							3x 2							
Sample B												38	38	100
(1) Photometric enzyme (GPO-PAP)		0,908	0,036	4	38		CVP	0,91	0,006	15%	0,773	1,05	38	
Other		0,91	0,036	4	35	0						35		
					3	0						3		
							3x 2							